Monday, November 14, 2022
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Filament Made Significant Progress In 3Q22. Filament Health Reported a 3Q22 loss of C$(1.3) million or C$(0.01) per share. The company continued to advance programs in several areas, including patient dosing in clinical trials, new product development, receiving three new patents, and raising C$2.5 million in a private placement. Cash on hand at the end of the quarter was C$3.5 million.
Clinical Trial Are Making Progress. During the quarter, the company announced the first dosing of PEX010, 25mg oral psilocybin, in an FDA-approved clinical trial. This trial will also test PEX020, oral psilocin, and PEX030, sublingual psilocin. Filament also announced that ATMA Journey Centers completed dosing of 14 patients using the psilocybin it had supplied through a collaborative agreement.
Get the Full Report
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.